Bell Potter Says This ASX Biotech Stock Could Rocket 80%

Paradigm Biopharmaceuticals Ltd (ASX: PAR) shares could have huge upside potential.

The Motley FoolMay 9 08:39

Paradigm Biopharmaceuticals Price Target Cut 66% to A$0.47/Share by Bell Potter

Paradigm Biopharmaceuticals Price Target Cut 66% to A$0.47/Share by Bell Potter

Dow JonesMay 9 06:21

Paradigm Biopharmaceuticals Submits Documents to FDA for Phase 3 Osteoarthritis Program

Paradigm Biopharmaceuticals (ASX:PAR) submitted key documents to the US Food and Drug Administration for review and agreement on the progression of its phase 3 clinical program in osteoarthritis, acco

MT NewswiresApr 19 08:32

Paradigm Biopharma's Injectable Pentosan Polysulfate Sodium Trial Reaches Endpoint

Paradigm Biopharma's (ASX:PAR) phase 2 clinical trial showed that pain eased in patients while using the injectable pentosan polysulfate sodium after the trial reached the primary endpoint. The trial

MT NewswiresFeb 12 15:22

Paradigm Biopharmaceuticals Limited (ASX:PAR) Is Expected To Breakeven In The Near Future

Yahoo FinanceFeb 12 06:17

Paradigm Biopharmaceuticals Secures AU$7 Million R&D Tax Incentive Rebate for Fiscal Year 2023; Shares Rally 9%

Paradigm Biopharmaceuticals (ASX:PAR) secured a AU$7.4 million rebate from the Australian government's research and development tax incentive scheme for the fiscal year ended June 30, 2023. The scheme

MT NewswiresFeb 7 11:11